HP when used in patients undergoing
INTRODUCTION embryo implantation potential, which is closely related to appropriate follicular development and oocyte competence.
Ovulation inducing drugs, mainly gonadotropins, are purification step using monoclonal antibodies and
Conclusions: rec-FSH is more efficacious than u-FSH-HP
involving removal of urinary proteins led to the clinical when used in the same patient in inducing multiple follicular availability of the third-generation gonadotropins development in down-regulated cycles as indicated by ovarian performance and oocyte maturity. In addition, rec-FSH known as highly purified FSH (u-FSH-HP), which is now the only marketed urinary FSH preparation (1,2). More recently, biotechnology has made available for 1 Institute Clinic of Gynecology, Obstetrics and Neonatology, Fac-the choice of gonadotropin for ovarian stimulation has male factor, tubal infertility, and minimal or mild endometriosis. All patients had undergone their first IVF been left to the physician. However, recent evidence comparing hMG and FSH and including the large dataattempt at our institution, having three or four embryos replaced but no pregnancy following an appropriate base of IVF treatment cycles in France, a meta-analysis of randomized controlled trials comparing FSH with ovarian response to gonadotropin stimulation using u-FSH-HP under pituitary suppression. hMG in IVF, in vitro studies on luteinized granulosa cells and oocyte morphology studies, suggests that For the main purpose of this study, which was the comparison of ovarian performance and estradiol levthe wisdom of continuing to use hMG for ovarian stimulation in IVF treatment should be reevaluated (5). els using u-FSH-HP and rec-FSH in IVF, 30 (group 1, or study group) consecutive patients fulfilling the In addition, recent studies comparing u-FSH (6) or u-FSH-HP (7) with rec-FSH in IVF concluded that recabove criteria and agreeing to be treated during their second IVF attempt with commercially available rec-FSH is more effective than urinary FSH in inducing multifollicular development.
FSH (Gonal-F; Serono S.A., Madrid, Spain) administered s.c., were treated using the same stimulation proHowever, any IVF general population is rather heterogeneous with respect to woman's age and ovarian tocol. As a control group (group 2) for implantation rates obtained in cycles treated with rec-FSH, 30 addireserve as well as indication for IVF, which in its turn may also affect the ovarian response to gonadotropin tional IVF patients were included. The control women were selected as follows: a patient who fulfilled the stimulation. Therefore, the use of the same treatment protocol applied to different gonadotropin drugs in the above-mentioned inclusion requirements and underwent a second IVF attempt immediately after a group same patient as previously done by us (8,9) and others (10, 11) seems the more appropriate study design when 1 patient but again receiving u-FSH-HP for ovarian stimulation (i.e., the closest consecutive cycle in temovarian performance and hormonal levels are the objectives to be compared. This was done in the present poral relationship to the index cycle). The time interval between treatment cycles in each woman was 6 to 13 study where the primary end point was to compare follicular development and estradiol levels after ovarmonths. Each patient underwent standard IVF or ICSI in both treatment cycles. ian stimulation in pituitary suppressed normally ovulating women undergoing IVF, using u-FSH-HP and rec-FSH. To the best of our knowledge, such a comparStimulation Regimen ative study has not been previously reported.
As a combined analysis of clinical trials comparing As reported previously (14) , ovarian stimulation for IVF is routinely accomplished using gonadotropins hMG and u-FSH with rec-FSH in IVF suggests that the latter yields significantly higher pregnancy rates under pituitary suppression with a GnRH agonist. Leuprolide acetate (Procrin; Abbott Laboratories S.A., than urinary gonadotropins (12), a secondary variable in our study was embryo implantation potential, which is closely related to appropriate follicular development 
MATERIALS AND METHODS
Age (y) 33.5 Ϯ 0.52 33.6 Ϯ 0.5 N.S. 
Patients Studied and Design
No. with indicated cause of infertility N.S.
In all, 60 primary infertility women from our IVF/ examination of the ovaries or basal gonadotropin mea- days after oocyte recovery, three or four embryos per patient were replaced (according to patient age and embryo quality) and the remaining embryos were cryopreserved. Additional doses of 5000, 2500, and 2500 Madrid, Spain) suppression is started in the midluteal IU of hCG were given on the day of follicle aspiration phase of the previous cycle at a daily dose of 1 mg and 2 and 5 days later, respectively, to supplement the s.c. This dose is reduced to 0.5 mg/day once ovarian luteal phase in all patients. Pregnancy was diagnosed arrest has been achieved and then is continued until by increasing serum concentrations of ␤-hCG 12 days the administration of hCG. Gonadotropin stimulation after embryo transfer and the subsequent demonstraof the ovaries was started when serum estradiol levels tion of an intrauterine gestational sac by ultrasonogdeclined to Ͻ50 pg/ml and a vaginal ultrasonographic raphy. scan showed an absence of follicles Ͼ10 mm in diameter. On days 1 and 2 of ovarian stimulation, 6 ampoules per day of u-FSH-HP (Neo-Fertinorm; Serono S.A.)
Hormone Analyses and Ultrasonography or rec-FSH (Gonal-F; Serono S.A.) was administered subcutaneously. On days 3 to 5 of ovarian stimulation, Hormone measurements and ultrasonographic scans were carried out as reported previously (14) . Hormones 2 ampoules per day of u-FSH-HP or rec-FSH was Table I , the main demographic the intraassay and interassay coefficients of variation and baseline characteristics of the patients in groups were Ͻ3.5 and 5.2%, respectively. Estradiol levels 1 and 2 were similar, including age, body mass index, in serum were estimated by direct RIA (BioMérieux, cause and duration of infertility, interval between IVF Marcy l'Etoile, France). Intraassay and interassay treatment cycles, and FSH level in the early follicular coefficients of variation were Ͻ4.5 and 5.5%, respecphase. It is noteworthy that basal FSH concentrations tively. Ultrasonographic scans were performed with a preceding the first and second IVF attempts were 5-MHz vaginal transducer attached to an Aloka sector almost-identical within groups. scanner (Model SSD-620; Aloka, Tokyo). Table II shows the data regarding ovarian response in the two gonadotropin stimulated IVF cycles in group 1. Time for ovarian arrest, days of ovarian stimulation, Statistics total dose of FSH administered, total number of growing follicles, and serum concentration of estradiol on Data were analyzed by SPSS statistical software the day of hCG injection were similar in both treatment using the chi-square test with Yates' correction when cycles. However, the number of follicles measuring necessary, the Wilcoxon matched-pairs signed-rank Ն14 mm in diameter on the hCG day was significantly test, the McNemar test, and the unpaired Student ttest, as appropriate. Data are presented as mean Ϯ SE.
higher in the rec-FSH-treated cycles. cycles (Table III) . Accordingly with final follicular development, a significantly higher number of metaphase II oocytes was found with rec-FSH treatment (Table IV) . No other significant differences were found between u-FSH-HP and rec-FSH treatment cycles regarding other oocyte and embryological characteristics summarized in Table IV . However, the interval between IVF and embryo transfer was longer in the rec-FSH treatment cycles (Table IV ). An analysis of the secondary end points (pregnancy and implantation rates) is presented in Table V , which compares embryo transfer and pregnancy in the two IVF treatment cycles in groups 1 and 2. The number of embryos per replacement was almost-identical in the four IVF cycles analyzed. There were 12 (40%) clinical pregnancies including one triplet and two pairs of twins with rec-FSH therapy. There was a first-trimester miscarriage in a patient having a single gestational sac in this study group.
There were no significant differences between the two IVF cycles in patients in group 2 with regard to ovarian response, ovum retrieval, and IVF outcome (data not shown). However, as with group 1, the interval between insemination of the oocytes and transfer of the embryos was significantly longer in the second IVF attempt in the control group of patients (group 2). There were seven (23%) clinical pregnancies in the latter group of women including a pair of twins. One of the six singleton pregnancies ended in spontaneous early abortion.
The comparison of pregnancy rates between the second IVF treatment cycles in groups 1 and 2 suggested a trend in favor of rec-FSH. The difference was statistically significant (P Ͻ 0.05) when implantation rates Table III and Fig. 1 are presented to analyze further follicular dynamics and estradiol levels during gonadoTo obtain multiple follicular development is a basic goal in IVF. This is accomplished with the combination tropin ovarian stimulation with u-FSH-HP and rec-FSH in patients in group 1. The serum estradiol conof GnRH agonists and gonadotropins in most IVF programs around the world. To stimulate follicular centration and the mean number of total growing follicles (Ͼ10 mm) related to the FSH treatment day are growth most IVF centers have used a supposedly equal mixture of FSH and LH in the form of hMG which depicted in Fig. 1 ; no significant differences were observed between gonadotropin treatment cycles with also contains urinary proteins. Apart from problems with urinary protein contamination, hMG may contain respect to any of both parameters. However, the number of follicles measuring Ն14 and Ն18 mm on FSH hCG to achieve an LH/FSH ratio of roughly 1:1. This hCG may accumulate and would explain some cases treatment day 10 and on the day of hCG injection, respectively, were significantly higher in the rec-FSH of premature luteinization and progesterone rise with potential detrimental effects on the ova or the endomeof 75 IU ampoules were both significantly lower in trium (16) . this treatment group. However, in both studies a 11% The use of hMG in IVF was based on traditional treatment difference with respect to the number of ovulation induction in cases of amenorrhea due to patients receiving hCG was observed in favor of rechypothalamic-pituitary failure and gonadotropin defi-FSH (7,20). This was due to a high incidence of canciency and on the belief that stimulation of the ovaries celed cycles because of low ovarian response in the under pituitary suppression would require supplemenu-FSH-HP group, where also the collection of only tation with LH (17) . The availability of u-FSH, u-FSHone or two oocytes at retrieval was higher than expec-HP, and, more recently, rec-FSH made it possible to ted (7). Accordingly, a higher proportion of patients discriminate better the relative roles of FSH and LH had only one embryo replaced in the u-FSH-HP group. in the ovulation process, underlining the key role of Despite this fact, however, there were no significant FSH in folliculogenesis. It is now well established that differences between the rec-FSH and the u-FSH-HP in women with normal pituitary function, treatment groups in the pregnancy rate per started cycle in the with FSH alone after pituitary suppression of endogestudy by either Bergh et al.
DISCUSSION

(7) or Frydman et al. (20). nous gonadotropin with a GnRH agonist results in
In these previously reported studies (7,20) the startnormal increases in estradiol, ovulation, and fertilizaing dose for both gonadotropin preparations was 150 tion, and thus supplementation with LH is not needed IU (2 ampoules) daily during the first 6 days. This (17) . Accordingly, in previous randomized clinical dosage may be too low in some patients, mainly those trials we showed that urinary FSH (either purified or receiving u-FSH-HP, if it definitely proves to be less highly purified) alone was as effective as hMG for effective than rec-FSH in inducing multiple follicular ovarian stimulation under pituitary desensitization development. During the stimulation process, both the (18) .
timing and the dose of FSH administered determine rec-FSH versus u-FSH with a GnRH agonist in a the number of follicles recruited and selected (21). long protocol has been analyzed in previous studies Follicular recruitment takes place in the late luteal and (6,19). In a multicenter study including a total of 981 early follicular phase of the menstrual cycle and each patients, Out et al. (6) found that a significantly higher follicle in the cohort has a "threshold" beyond which number of oocytes was retrieved with a lower total it is stimulated by FSH to start preovulatory developdose of FSH over a shorter treatment period among ment, otherwise it becomes atretic (22). The so-called patients receiving rec-FSH, but there were no differintercycle increase in bioactive FSH secretion plays ences between the two groups in implantation rates or an essential role in this respect in the spontaneous clinical pregnancy rates. In the study by Hedon et al. menstrual cycle. (19) including 99 patients, results were in the same It has been shown that for successful induction of direction but the higher efficacy of rec-FSH compared multiple folliculogenesis in normally ovulating women with u-FSH was apparently not significant, probably there is a critical period during the early follicular because of the small sample size. This is further supphase of the cycle when FSH values should remain ported by a meta-analysis including three comparative above the physiological level to stimulate follicle studies on rec-FSH and urinary gonadotropins which recruitment maximally in the primary cohort, and folliindicated that the ongoing pregnancy rate per started cles recruited by exogenous FSH require an FSH cycle was significantly higher for rec-FSH (22.9 versus threshold level that is higher than that in the natural 17.9%) (12). However, in one of the trials the active cycle (23). Interestingly, such a threshold level was agent was hMG and no pituitary desensitization was reached in that study with a single injection of 6 used (12).
ampoules of u-FSH on cycle day 2 and further growth At present, the point is whether rec-FSH is more of the follicles was obtained with extra FSH from cycle effective and may yield higher pregnancy rates in day 4 onward at a daily dose of 2 ampoules (23), an down-regulated IVF patients than u-FSH-HP, which approach which mimics that one used in the present is now the only marketed urinary FSH preparation and study. Therefore, our gonadotropin treament regimen a product with a specific activity that approaches that seems more appropriate than those used in previous of rec-FSH and that can also be injected subcutane-IVF studies comparing rec-FSH and u-FSH-HP in ously. Two recent studies deal with this topic (7, 20) order to exceed individual follicular threshold requireand both concluded that the mean number of oocytes ments for FSH and thereby stimulate multiple follicular recovered was significantly higher in the rec-FSH group, despite that the treatment duration and number development in most IVF patients.
On the other hand, it is important to emphasize In summary, this study has demonstrated that rec-FSH is more efficacious than u-FSH-HP when used that marked interindividual variation exists in FSH in the same patient in inducing multiple follicular thresholds as well as in FSH metabolic clearance and development in down-regulated cycles as indicated ovarian sensitivity to FSH (24) (25) (26) . Thus, from the by ovarian performance and oocyte maturity obtained beginning of IVF it has been known that healthy using the same amount of FSH. In addition rec-FSH women with comparable weights and a normal menyields significantly higher implantation rates than ustrual cycle may react differently to the same dose of FSH-HP when used in patients undergoing their second gonadotropins. Therefore, as discussed above, the use IVF attempt. Further studies appropiately designed of the same treatment protocol applied to different comparing both gonadotropin preparations in the same drugs in the same patient as done in the present study patient are warranted to show the superiority of recseems more appropriate to compare ovarian perfor-FSH over u-FSH-HP in terms of pregnancy rates after mance and hormonal levels. Thus, a feature of our assisted reproductive techniques. Considering the difstudy is that each woman was her own control for ference in pregnancy rates between the second treatovarian activity and hormonal changes. ment cycles in groups 1 and 2 obtained in our study, Our results indicate that both gonadotropin preparaa sample size of 256 patients would be necessary in tions are clinically useful but rec-FSH may have a order to provide an 80% statistical power of avoiding higher biopotency compared with u-FSH-HP. The fola type II error and a 5% chance of making a type I error. lowing facts support this contention. First, the fact that the treatment cycles with u-FSH-HP and rec-FSH in patients in group 1 were almost-identical with respect to days of ovarian stimulation, total dose of FSH used, REFERENCES total number of growing follicles and estradiol levels throughout the stimulation period, number of patients 
